Argenx, a biotechnology company with several promising treatments in its pipeline, has been gaining significant attention for its expanded global partnerships, most notably with
FUJIFILM Biotechnologies that now includes U.S. manufacturing operations. With this expansion, Argenx aims to produce
Vyvgart in the U.S. with a target price of $850. Argenx recently completed a '
Phase 1 Study' on '
ARGX-109', providing key insights for investors. It also announced positive topline results from its '
ADAPT SERON'. Argenx's multiple drug innovations like '
Vyvgart' has received European Commission approval for use in CIDP treatment. After a successful earnings beat report, both '
Oppenheimer' and '
RBC' have reiterated an 'outperform' rating on Argenx stock, and the stock has reached an all-time high. The company is expanding its autoimmune leadership with the launch of
Vyvgart, and seeking broader myasthenia gravis label for Vyvgart. But it's also worth noting that Deutsche Bank downgraded Argenx to 'hold' after a 40% rally.
argenx News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 20 Sep 2025 21:47:15 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -4
